ArticleCurrent treatment options in neurology2011
Immunotherapy of inflammatory myopathies: practical approach and future prospects.
Article in Current treatment options in neurology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: a systematic literature review.Clinical rheumatology · 2012Pooled it
- The Myositis Overlap Conundrum: Differentiating Polymyositis from Inclusion Body Myositis.Juntendo medical journal · 2026Article
- The caregiver burden of idiopathic inflammatory myopathies.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Lung involvement is a risk factor for treatment resistance in patients with polymyositis and dermatomyositis.Archives of rheumatology · 2025Article
- Clinical Characteristics of Dermatomyositis with Interstitial Lung Disease: A Retrospective Case-Control Study.Rheumatology and therapy · 2023Article
- Management of dermatomyositis patients amidst the COVID-19 pandemic: Two case reports.Medicine · 2022Article
- Article
- Supervised Physical Therapy and Polymyositis/Dermatomyositis-A Systematic Review of the Literature.Neurology international · 2020Review
- Polymyositis and dermatomyositis - challenges in diagnosis and management.Journal of translational autoimmunity · 2019Article
- Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies.Current treatment options in neurology · 2018Review
- Idiopathic Inflammatory Myopathies: Clinical Approach and Management.Frontiers in neurology · 2016Review
- Future perspectives in target-specific immunotherapies of myasthenia gravis.Therapeutic advances in neurological disorders · 2015Review
- Cost-utility analysis of intravenous immunoglobulin for the treatment of steroid-refractory dermatomyositis in Thailand.PharmacoEconomics · 2015Article
- Targeted immunotherapy trials for idiopathic inflammatory myopathies.Journal of neurology · 2013Review
- Antiangiogenic VEGF isoform in inflammatory myopathies.Mediators of inflammation · 2013Article
- Diagnosis and treatment of inflammatory myopathy: issues and management.Therapeutic advances in musculoskeletal disease · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementThe inflammatory myopathies, a group of chronic myopathic conditions, are potentially treatable, so proper diagnosis and early initiation of therapy are necessary. The most common types are polymyositis (PM), dermatomyositis (DM), necrotizing autoimmune myopathy (NAM), and inclusion body myositis (IBM). This review provides practical advice on treatment and identifies emerging new therapies. Although IBM is difficult to treat, PM, DM, and NAM respond to appropriate immunotherapies, if diagnosed early and treated aggressively. In uncontrolled studies, PM and DM respond to prednisone to some degree and for a period of time. The commonly used immunosuppressive drugs (azathioprine, cyclosporine, mycophenolate, or methotrexate) may offer some non-evidence-based "steroid-sparing" effect but provide minimal benefit on their own. As a result, the second-line therapy is intravenous immunoglobulin (IVIg), which a controlled study has shown to be effective in DM and which appears to be effective in PM and NAM; it offers minimal and transient benefit to only a small number of IBM patients, however. Uncontrolled series have suggested that rituximab and tacrolimus may offer additional benefit to some patients not adequately controlled with the aforementioned therapies. IBM is usually resistant to most therapies, but early initiation of therapy may be helpful at times. Emerging agents against T cells, B cells, transmigration, or transduction molecules are discussed as potential new treatment options.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.